trending Market Intelligence /marketintelligence/en/news-insights/trending/jV-nar_IfDYicjnOfiHybw2 content esgSubNav
In This List

US FDA accepts Sun Pharma application for eye treatment

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


US FDA accepts Sun Pharma application for eye treatment

Sun Pharmaceutical Industries Ltd. said the U.S. Food and Drug Administration accepted its new drug application for Seciera, a treatment for the dry eye disease.

The treatment, a clear aqueous solution, is now under review for approval by the regulator.

Once approved, Sun Pharma plans to commercialize Seciera in the U.S. through its subsidiary Sun Ophthalmics Inc.

Seciera, also known as OTX-101, previously met its main and secondary goals in a phase 3 trial in patients with the disease.